This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Thermage

Thursday proved to be another droopy day for health stocks, as news kept on the light side and investor sentiment continued to mimic the broader markets.

The Nasdaq and Amex biotechnology indices were down 0.8% and 0.7%, respectively. The Amex Pharmaceutical Index was off by just 0.07%.

Pharma components Bristol-Myers Squibb (BMY - Get Report) and AstraZeneca (AZN - Get Report) managed to buck the trend, gaining 1.7% and 1.8%, respectively.

Thermage (THRM - Get Report) soared Thursday after the company said it received a revised unsolicited bid from a third party, putting its pending acquisition of Reliant Technologies in doubt.

Thermage, which makes devices for wrinkle treatments, would receive $5.50 a share in cash or a combination of cash and stock in the third-party bid. The company, which in July that it would buy the laser skin resurfacing company Reliant Technologies for $87.5 million in cash and stock, said its board will consider the proposal and respond in due course. If it accepts the bid, it would scrap the Reliant deal. Thermage shares rose $1.32, or 43.7%, to $4.34.

In clinical news, Bayer and Onyx (ONXX) said Thursday that they have begun enrolling patients in a late-stage study, dubbed STORM, on Nexavar as an adjuvant treatment for prevention of recurrence of hepatocellular carcinoma, or primary liver cancer, following surgery or local radiation. The company said the Food and Drug Administration has completed a special protocol assessment (SPA) -- an agreement on the design and size of a trial meant to be the basis for a new drug application -- for the STORM trial.

Onyx shares, however, were off by 52 cents, or 1.2%, at $41.57.

In analyst actions, Lazard upgraded ArthroCare (ARTC) to buy from hold, with a $38 price target. Its shares were up $1.20, or 4.8%, at $26.37.

Also, Leerink Swann initiated coverage of Jazz Pharmaceuticals (JAZZ - Get Report) with a market perform rating. Jazz shares were down 36 cents, or 4.5%, at $7.71.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
ARTC $48.60 0.08%
BMRN $80.74 -1.70%
BMY $71.15 0.52%
AZN $28.10 -0.57%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs